Development of Piperine-Loaded Solid Self-Nanoemulsifying Drug Delivery System: Optimization, In-Vitro, Ex-Vivo, and In-Vivo Evaluation.
antihypertensive activity
antimicrobial activity
oral delivery
piperine
solid self nanoemusifying
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
31 Oct 2021
31 Oct 2021
Historique:
received:
11
09
2021
revised:
28
10
2021
accepted:
29
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Hypertension is a cardiovascular disease that needs long-term medication. Oral delivery is the most common route for the administration of drugs. The present research is to develop piperine self-nanoemulsifying drug delivery system (PE-SNEDDS) using glyceryl monolinoleate (GML), poloxamer 188, and transcutol HP as oil, surfactant, and co-surfactant, respectively. The formulation was optimized by three-factor, three-level Box-Behnken design. PE-SNEDDs were characterized for globule size, emulsification time, stability, in-vitro release, and ex-vivo intestinal permeation study. The optimized PE-SNEDDS (OF3) showed the globule size of 70.34 ± 3.27 nm, percentage transmittance of 99.02 ± 2.02%, and emulsification time of 53 ± 2 s Finally, the formulation OF3 was transformed into solid PE-SNEDDS (S-PE-SNEDDS) using avicel PH-101 as adsorbent. The reconstituted SOF3 showed a globule size of 73.56 ± 3.54 nm, PDI of 0.35 ± 0.03, and zeta potential of -28.12 ± 2.54 mV. SEM image exhibited the PE-SNEDDS completely adsorbed on avicel. Thermal analysis showed the drug was solubilized in oil, surfactant, and co-surfactant. S-PE-SNEDDS formulation showed a more significant (
Identifiants
pubmed: 34835684
pii: nano11112920
doi: 10.3390/nano11112920
pmc: PMC8624913
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Taif University Researchers Supporting Project number Taif University, Taif, Saud Arabia.
ID : (TURSP-2020/50),
Références
Pharmaceuticals (Basel). 2020 Jul 24;13(8):
pubmed: 32722238
Antibiotics (Basel). 2019 May 04;8(2):
pubmed: 31060239
Biomed Res Int. 2018 Sep 27;2018:6763057
pubmed: 30363745
J Pharm Biomed Anal. 2015 Nov 10;115:144-9
pubmed: 26201645
Molecules. 2020 Oct 14;25(20):
pubmed: 33066657
Drug Deliv. 2015;22(6):740-7
pubmed: 24670090
Colloids Surf B Biointerfaces. 2013 Dec 1;112:337-43
pubmed: 24012665
Int J Biol Macromol. 2018 Jan;106:425-432
pubmed: 28802847
AAPS PharmSciTech. 2012 Dec;13(4):1416-27
pubmed: 23070560
Int J Nanomedicine. 2019 Jul 05;14:4949-4960
pubmed: 31308665
AAPS PharmSciTech. 2016 Oct;17(5):1240-7
pubmed: 26573159
Pharmaceutics. 2020 Jul 25;12(8):
pubmed: 32722400
Eur J Pharm Biopharm. 2011 Oct;79(2):250-7
pubmed: 21550401
Drug Dev Ind Pharm. 2016;42(2):288-306
pubmed: 26087658
Int J Immunopharmacol. 2000 Sep;22(9):729-40
pubmed: 10884593
Int J Pharm. 2018 Mar 1;538(1-2):40-47
pubmed: 29294324
Int J Nanomedicine. 2019 Jul 18;14:5435-5448
pubmed: 31409997
Oxid Med Cell Longev. 2019 Apr 16;2019:1309175
pubmed: 31178949
Drug Deliv Transl Res. 2021 Feb;11(1):118-130
pubmed: 32016707
ISRN Pharm. 2012;2012:195727
pubmed: 22830056
Pharmaceutics. 2020 May 06;12(5):
pubmed: 32384817
J Adv Res. 2016 May;7(3):423-34
pubmed: 27222747
Biomed Res Int. 2017;2017:6761452
pubmed: 28884127
J Microencapsul. 2017 May;34(3):319-333
pubmed: 28481663
Int J Nanomedicine. 2015 Jul 29;10:4797-813
pubmed: 26251598
J Cardiovasc Pharmacol. 2008 Nov;52(5):452-8
pubmed: 19033825
Front Bioeng Biotechnol. 2020 May 14;8:425
pubmed: 32478050
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
Pharmaceutics. 2020 Aug 04;12(8):
pubmed: 32759764
Eur J Pharm Sci. 2019 Sep 1;137:104988
pubmed: 31291598
Planta Med. 2019 Feb;85(3):249-257
pubmed: 30357764
Biomaterials. 2012 Oct;33(28):6758-68
pubmed: 22748771
Int J Nanomedicine. 2021 Feb 09;16:905-924
pubmed: 33603359